Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Sintilimab

Sintilimab

Sintilimab is a monoclonal antibody that targets the programmed cell death-1 (PD-1) receptor, a key immune checkpoint protein involved in regulating T-cell activation and function.
It is used in the treatment of certain types of cancer by enhancing the body's immune response agaisnt tumor cells.
Sintilimab has been shown to be effective in clinical trials for various solid tumors and hematological malignancies.
Researchers can leverage PubCompare.ai to optimize their Sintilimab studies and enhance reproducibility by exploring the latest literature, pre-prints, and patents on this important cancer immunotherapy.

Most cited protocols related to «Sintilimab»

1
ORIENT-15: Sintilimab for Esophageal Cancer
Cited 6 times
ORIENT-15 was a multicentre, double blind, randomised, phase 3 clinical trial conducted at 79 sites in five countries (China, France, Spain, US, and Australia; table S2). The ORIENT-15 trial was started in China in December 2018. While our study was ongoing, other studies that enrolled patients with oesophageal squamous cell carcinoma globally reported that anti-PD-1 monoclonal antibodies prolonged overall survival in those who progressed after first line chemotherapy,8 (link)
9 (link) and therefore we expanded our trial to include western countries. Based on communications with the US Food and Drug Administration, the chemotherapy regimen of cisplatin plus 5-fluorouracil, used globally, was added as a chemotherapy option in our trial. In February 2020, our trial was amended to a multiregional trial and the number of patients enrolled was increased to 676. We enrolled 62% of patients (420/676) before February 2020 but the first patient outside of China was enrolled on 25 November 2020 because of the covid-19 pandemic. At that time, 95% of the target number of patients (640/676) had been enrolled in China.
In January 2021, one of the primary endpoints of the trial was changed from overall survival in patients with tumour proportion scores ≥10% for expression of programmed cell death ligand 1 (PD-L1 TPS), to overall survival in patients with combined positive scores ≥10 for expression of programmed cell death ligand 1 (PD-L1 CPS). This change was based on the results of KEYNOTE-181 (A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-line Standard Therapy) and KEYNOTE-590, suggesting that the combined positive score might be better associated with the benefits of anti-PD-1 treatment than the tumour proportion score.8 (link)
19 (link) Up to January 2021, 95% of patients (644/676) had been enrolled in the trial based on the tumour proportion score as one of the stratification factors, and therefore the stratification factor during enrolment could not be changed from the tumour proportion score to the combined positive score. After January 2021, enrolment outside of China was ongoing whereas enrolment in China had ended when one of the primary endpoints of the trial was changed from overall survival in patients with PD-L1 TPS≥10% to overall survival in patients with PD-L1 CPS≥10.
Based on the positive results of the interim analysis, sintilimab in combination with chemotherapy significantly prolonged the overall survival of patients compared with placebo in combination with chemotherapy. But only 19 patients outside of China had been randomised before 9 April 2021 (cut-off date of the interim analysis). Enrolment in the randomisation phase was still ongoing outside of China. To further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in patients representing western populations with advanced or metastatic oesophageal squamous cell carcinoma, a single arm open label extension phase will be conducted outside of China after completion of enrolment in the randomisation phase. Seventy patients will receive sintilimab combined with chemotherapy in the open label phase. The protocol was amended after the interim analysis in August 2021.
The trial was done according to Good Clinical Practice and the Declaration of Helsinki. The protocol and amendments were approved by the institutional review board or ethics committee at each site.
Lu Z., Wang J., Shu Y., Liu L., Kong L., Yang L., Wang B., Sun G., Ji Y., Cao G., Liu H., Cui T., Li N., Qiu W., Li G., Hou X., Luo H., Xue L., Zhang Y., Yue W., Liu Z., Wang X., Gao S., Pan Y., Galais M.P., Zaanan A., Ma Z., Li H., Wang Y., Shen L., Pan Z., Zhang S., Lin G., Xie Y., Li T., Ren T., Li W., Gu K., Wang S., He W., Xia B., Fan Y., Liang J., Zhao K., Pan H., Xu N., Cheng Y., Gao Q., Sun P., Zang A., Zheng A., Luo Z., Liu T., Ding S., Xu T., Li W., Liu F., Cang S., Wang J., Lin X., Jiang D., Mao R., Ma D., Liu Y., Tao M., Tang Y., Chen X., Chen P., Feng G., Yang Z., Zhang G., Zhang X., Huang Y., Lee F.C., Dean A., El Hajbi F., Ghiringhelli F., Borg C., Tougeron D., Dahan L., Pernot S., Rivera F., Pazo Cid R.A, & Vazquez Rivera M.F. (2022). Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. The BMJ, 377, e068714.
Publication 2022
2
Cost-Effectiveness Analysis of First-Line Treatments for Advanced Esophageal Squamous Cell Carcinoma
Cited 5 times
This study was guided by the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) updated reporting guidelines (Supplementary Table S1) (Husereau et al., 2022 (link)). This economic evaluation was based on modelling techniques and published literature, and did not require approval of the institutional research ethics board because no real human participants or animals were involved.
A hypothetical cohort of patients, aged at least 18 years, with histologically or cytologically confirmed unresectable locally advanced, recurrent, or metastatic ESCC with the same characteristics as those patients enrolled in ESCORT-first (Luo et al., 2021 (link)), CheckMate-648 (Doki et al., 2022 (link)), KEYNOTE-590 (Sun et al., 2021 (link)), ASTRUM-007 (Song et al., 2023 (link)), ORIENT-15 (Lu et al., 2022 (link)) and JUPITER-06 (Wang et al., 2022 (link)) clinical trials. Eligible patients received one of seven first-line interventions: (1) Chemotherapy (Cisplatin, 75 mg/m2, day 1 plus Paclitaxel, 175 mg/m2, day 1 or Fluorouracil, 800 mg/m2, days 1 through 5; 3-week); (2) Camrelizumab (200 mg; 3-week) plus chemotherapy; (3) Nivolumab (240 mg; 2-week) plus chemotherapy; (4) Pembrolizumab (200 mg; 3-week) plus chemotherapy; (5) Serplulimab (75 mg/kg; 2-week) plus chemotherapy; (6) Sintilimab (200 mg; 3-week) plus chemotherapy; (7) Toripalimab (240 mg; 3-week) plus chemotherapy (Supplementary). After disease progression, we assumed that the remaining patients would receive subsequent best supportive anti-cancer regimens to accurately capture the cost-effectiveness associated with first-line treatment.
Liu S., Dou L, & Li S. (2023). Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China. Frontiers in Pharmacology, 14, 1055727.
Full text: Click here
Publication 2023
Animals Antineoplastic Protocols Asian Persons camrelizumab Cisplatin Disease Progression Fluorouracil Homo sapiens Nivolumab Paclitaxel Patients pembrolizumab Pharmacotherapy sintilimab toripalimab
3
Sintilimab Plus Chemotherapy for ESCC
Cited 4 times
Every three weeks, all patients received sintilimab or placebo combined with chemotherapy. The chemotherapy regimen was chosen by the investigator: cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil. Sintilimab or placebo was given intravenously at a dose of 3 mg/kg in patients weighing <60 kg or 200 mg in patients weighing ≥60 kg on day 1 of each cycle. Cisplatin (75 mg/m2 on day 1 of each cycle) plus paclitaxel (87.5 mg/m2 on day 1 and day 8 of cycle 1; 175 mg/m2 on day 1 of the other cycles) or 5-fluorouracil (800 mg/m2 continuous administration on days 1-5 of each cycle) were also given intravenously. A maximum of six cycles was recommended for chemotherapy. Treatment with sintilimab or placebo was continued until progressive disease, intolerable toxicity, the start of new antitumour treatment, withdrawal of consent, lost to follow-up, death, completion of treatment, or any other reasons determined by the investigators for stopping treatment, whichever occurred first.
Sintilimab or placebo was continued for a maximum of 24 months. Sintilimab or placebo was used alone if chemotherapy was intolerable, or when six cycles of chemotherapy had been given. The choice of chemotherapy regimen (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) could not be switched during the study. Appendix 2 provides more details of the study design.
Assessments of the tumours were performed by the investigators according to RECIST version 1.1 at baseline, once every six weeks for 48 weeks, and then once every 12 weeks. Adverse events were assessed up to 90 days after the last dose and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Survival was assessed every 60 days during follow-up.
Expression of PD-L1 in fresh or archival tumour sample was assessed during screening at a central laboratory (Covance, Shanghai, China) with the PD-L1 immunohistochemistry 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, USA). The combined positive score was defined as the number of PD-L1 staining cells (tumour cells, lymphocytes, and macrophages) divided by the total number of viable tumour cells. The tumour proportion score was defined as the percentage of viable tumour cells showing partial or complete membrane staining.
Lu Z., Wang J., Shu Y., Liu L., Kong L., Yang L., Wang B., Sun G., Ji Y., Cao G., Liu H., Cui T., Li N., Qiu W., Li G., Hou X., Luo H., Xue L., Zhang Y., Yue W., Liu Z., Wang X., Gao S., Pan Y., Galais M.P., Zaanan A., Ma Z., Li H., Wang Y., Shen L., Pan Z., Zhang S., Lin G., Xie Y., Li T., Ren T., Li W., Gu K., Wang S., He W., Xia B., Fan Y., Liang J., Zhao K., Pan H., Xu N., Cheng Y., Gao Q., Sun P., Zang A., Zheng A., Luo Z., Liu T., Ding S., Xu T., Li W., Liu F., Cang S., Wang J., Lin X., Jiang D., Mao R., Ma D., Liu Y., Tao M., Tang Y., Chen X., Chen P., Feng G., Yang Z., Zhang G., Zhang X., Huang Y., Lee F.C., Dean A., El Hajbi F., Ghiringhelli F., Borg C., Tougeron D., Dahan L., Pernot S., Rivera F., Pazo Cid R.A, & Vazquez Rivera M.F. (2022). Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. The BMJ, 377, e068714.
Publication 2022
Antineoplastic Combined Chemotherapy Protocols Biological Assay CD274 protein, human Cells Cisplatin Fluorouracil Immunohistochemistry Lymphocyte Macrophage Neoplasms Paclitaxel Patients Pharmacotherapy Placebos sintilimab Tissue, Membrane TP protocol Treatment Protocols
4
Sintilimab Plus Chemotherapy for Esophageal Cancer
Cited 3 times
All efficacy endpoints were assessed in the intention-to-treat population of patients who were randomised. Safety was assessed in all patients who received at least one dose of the study treatment. The statistical analysis plan specified one interim analysis and a final analysis.
Median overall survival, progression free survival, duration of response, and corresponding 95% confidence intervals were estimated by the Kaplan-Meier method, and survival curves were plotted. A stratified log rank test was used to compare overall survival and progression free survival between treatment groups. Hazard ratios (95% confidence intervals) were estimated with a stratified Cox proportional hazards model where the stratification factors were PD-L1 CPS, ECOG performance status score, chemotherapy regimen, and hepatic metastasis. The objective response rate and disease control rate with corresponding 95% confidence intervals for each treatment group were estimated with normal approximation. Differences and 95% confidence intervals in objective response rates between the treatment groups were calculated with Miettinen-Nurminen methods.
We estimated that enrolling 676 patients to observe 500 overall survival events, and 240 overall survival events in patients with PD-L1 CPS ≥10, would provide a power of 83% to detect a hazard ratio of 0.75 in all patients and a power of 86% to detect a hazard ratio of 0.65 in patients with PD-L1 CPS ≥10 for overall survival favouring sintilimab in combination with chemotherapy over placebo in combination with chemotherapy, respectively. The overall type I error of the hypothesis testing for the two primary endpoints of overall survival was controlled by first assigning a one sided α of 0.0125 to all patients and a one sided α of 0.0125 to patients with PD-L1 CPS ≥10. The two primary hypotheses (superiority of sintilimab with chemotherapy v chemotherapy only for overall survival in all patients and in patients with PD-L1 CPS ≥10) were tested in parallel. If the test in any population was significant, all α values allocated to that population were transferred to the other population. If the primary analyses for both populations were significant, the key secondary endpoints were tested in the sequence of objective response rate in all patients, progression free survival in all patients, objective response rate in patients with PD-L1 CPS ≥10, and progression free survival in patients with PD-L1 CPS ≥10.
The interim analysis was planned at about 70% overall survival events in all patients (350 overall survival events) and in patients with PD-L1 CPS ≥10 (168 overall survival events). The preset 70% overall survival events, however, did not occur at the same time in all patients and in patients with PD-L1 CPS ≥10. According to the prespecified conditions in the protocol, the interim analysis was performed at 351 overall survival events (about 70% overall survival events) in all patients; there were 195 overall survival events in patients with PD-L1 CPS ≥10 at this time. On the basis of the observed number of overall survival events, the threshold of one sided α for the interim analysis of overall survival was 0.0028 in all patients and 0.0056 in patients with PD-L1 CPS ≥10. The type I error boundary for the interim analysis was determined with the Lan-DeMets spending function in combination with the O'Brien-Fleming boundary in both populations. The independent data monitoring committee confirmed that the study met the specified efficacy and safety endpoints after reviewing the results of the interim analysis by an unblinded external statistics team.
Health related quality of life was assessed by the questionnaires QLQ-C30 (quality of life questionnaire-core 30), QLQ-OES18 (quality of life questionnaire-oesophageal cancer module 18), and EQ-5D-5L (five level EuroQol five dimensional questionnaire) as exploratory endpoints. Time to deterioration (defined as first decline in standard score of ≥10 from baseline) in the global health status/quality of life domain of the QLQ-C30 and the pain, eating, reflux, and dysphagia domains of the QLQ-OES18 were compared with a stratified log rank test and Cox proportional hazard model, and the Kaplan-Meier method. The change from baseline in the visual analogue scale of the EQ-5D-5L was compared with a mixed model for a repeated measures approach, with treatment group, visit, treatment-by-visit interaction, randomisation group, baseline, and baseline-by-visit interaction as covariates. Least squares means in each treatment group and differences between groups were calculated, with corresponding standard errors and 95% confidence intervals. All statistical analyses were conducted with SAS version 9.2 (or higher). An independent data monitoring committee reviewed safety and interim efficacy.
Lu Z., Wang J., Shu Y., Liu L., Kong L., Yang L., Wang B., Sun G., Ji Y., Cao G., Liu H., Cui T., Li N., Qiu W., Li G., Hou X., Luo H., Xue L., Zhang Y., Yue W., Liu Z., Wang X., Gao S., Pan Y., Galais M.P., Zaanan A., Ma Z., Li H., Wang Y., Shen L., Pan Z., Zhang S., Lin G., Xie Y., Li T., Ren T., Li W., Gu K., Wang S., He W., Xia B., Fan Y., Liang J., Zhao K., Pan H., Xu N., Cheng Y., Gao Q., Sun P., Zang A., Zheng A., Luo Z., Liu T., Ding S., Xu T., Li W., Liu F., Cang S., Wang J., Lin X., Jiang D., Mao R., Ma D., Liu Y., Tao M., Tang Y., Chen X., Chen P., Feng G., Yang Z., Zhang G., Zhang X., Huang Y., Lee F.C., Dean A., El Hajbi F., Ghiringhelli F., Borg C., Tougeron D., Dahan L., Pernot S., Rivera F., Pazo Cid R.A, & Vazquez Rivera M.F. (2022). Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. The BMJ, 377, e068714.
Publication 2022
5
Cost-Effectiveness Analysis of Adebrelimab
Cited 3 times
We only considered the direct medical costs, including the cost of drugs, tests, follow-up, end-of-life care, and management of adverse reactions of grade 3 or higher with an incidence greater than 5% (Table 1). The cost of drugs was obtained from the national tender prices (Yaozhi Net, 2022 ). However, adebrelimab is not yet on the market, and thus, we could not obtain its exact price. We estimated the plausible price of adebrelimab in China (converted to the price required per cycle) based on the price of sintilimab (Yaozhi Net, 2022 ), a drug developed in China ($334.9/200 mg). Other costs were sourced from published literature and adjusted to the prices in 2021 using the China Statistics Bureau Medical Price Index (National Bureau of Statistics, 2021 ). All costs were converted using the average exchange rate in 2021 and expressed in US dollars ($1 = 6.45 RMB). It should be pointed out that apart from body weight, body surface area, and creatinine clearance, no other parameters can affect the cost of drugs. As the relevant data on the quality of life were not available in the CAPSTONE-1 trial (Wang et al., 2022 (link)), the utility of PFS and PD was assessed from published literature in China (Table 1) (Kang et al., 2021 (link)). We considered the disutility of adverse reactions of grade 3 or higher with an incidence greater than 5% to reduce the impact of using the same utility values for both treatment groups in the model. Both costs and health utilities were discounted, and the discounted values were set at 5% per year (Table 1) (Liu et al., 2011 ).
You M., Chen R., Wu Q., Zhu W., He Y, & Huang Y. (2022). Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer. Frontiers in Pharmacology, 13, 1019826.
Full text: Click here
Publication 2022
Body Surface Area Body Weight Creatinine Hospice Care Pharmaceutical Preparations sintilimab

Most recents protocols related to «Sintilimab»

1
Short-course Sintilimab Plus Nab-paclitaxel/Platinum for sq-NSCLC
This was a prospective, multi-center, open-label, single-arm, phase 2 clinical trial registered with the Chinese Clinical Trial Registry (link: https://www.chictr.org.cn/, number: ChiCTR1900021726, date: 07/03/2019). It was originally designed and registered as version 1.0 on December 26, 2018 with the protocol of a randomized controlled phase 2 clinical study of short-course chemotherapy of paclitaxel/platinum with sintilimab versus paclitaxel/platinum as first-line treatment for locally advanced or metastatic sq-NSCLC in Chinese patients. PD-1 inhibitors in combination with chemotherapy became the standard treatment for advanced sq-NSCLC in 2019, so chemotherapy alone was no longer an acceptable therapy. Thus, we modified the protocol (V2.1, April 26, 2020) to sintilimab combined with two cycles (short-course) nab-paclitaxel/platinum as first-line therapy for locally advanced or metastatic sq-NSCLC in a phase 2, single-arm clinical study, here reported.
Eligible patients received sintilimab (100 mg/10 ml, 200 mg) with albumin paclitaxel (260 mg/m²) plus carboplatin (AUC = 5) by intravenous infusion every 3 weeks for 2 cycles, followed by maintenance therapy with sintilimab until PD, intolerable toxicity, death or up to 2 years. In the case of discontinuation of sintilimab due to AEs, administration of sintilimab could be interrupted for up to 12 weeks. Dose reductions were permitted for chemotherapy, but not for sintilimab.
Blood was obtained within 1 h prior to the administration of the initial treatment (C0), after cycle 1 of treatment (C1), after cycle 2 (C2) and at the time of PD. Serum was separated and stored at −80 °C for subsequent testing.
Zhang M., Zhang G., Niu Y., Zhang G., Ji Y., Yan X., Zhang X., Wang Q., Jing X., Wang J., Ma Z, & Wang H. (2024). Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial. Nature Communications, 15, 1512.
Full text: Click here
Publication 2024
2
Retrospective Study of Sintilimab in Oncology
Data of patients treated with sintilimab at the Union Hospital Affiliated to Fujian Medical University from January 2015 to May 2022 were retrospectively collected, including patient characteristics (such as age, sex, and alcohol and smoking history), disease characteristics (tumor type, tumor surgical history, pulmonary metastasis, brain metastasis, and number of metastatic sites), characteristics of comorbidities (such as hypertension, diabetes, coronary heart disease, stroke, chronic obstructive pulmonary disease, hepatitis, and syphilis), previous medication history (e.g., chemotherapeutics, targeted drugs, and other PD‐1s), combination therapy (e.g., chemotherapy, targeted drugs, antimicrobials, sputum agents, anti‐asthmatics, glucocorticoids, proton pump inhibitors [PPIs], or pirfenidone), treatment regimen of sintilimab (cycle and single dose), and hematological examination results (routine blood testing, electrolytes, lactate dehydrogenase, liver function, kidney function, and thyroid function indicators). Laboratory index ratios were calculated using the following methods: platelet‐lymphocyte ratio (PLR) = platelet count (×109 cells/L)/lymphocyte count (×109 cells/L) and neutrophil‐to‐lymphocyte ratio (NLR) = absolute neutrophil count (×109 cells/L)/lymphocyte count (×109 cells/L). Clinical data on IRP were collected retrospectively and classified according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
15
The inclusion criterion for this study was having tumors and receiving sintilimab. The exclusion criteria were as follows: (a) age <18 years, (b) treatment with a combination of sintilimab and other ICIs, (c) dropping out during follow‐up, and (d) missing data. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Fujian Union Medical College Hospital. Due to the retrospective nature of this study, the requirement for written informed consent was waived.
Hong B., Chen R., Zheng C., Liu M, & Yang J. (2024). Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment. Cancer Medicine, 13(3), e6708.
Full text: Click here
Publication 2024
3
Combination Therapy for HCC Patients
All patients were treated with lenvatinib every day and sintilimab intravenously once every 3 wk. Moreover, TACE was performed every 4-6 wk if there was obvious hepatic arterial blood supply to the HCC lesion according to contrast-enhanced abdominal magnetic resonance imaging or computed tomography combined with changes in tumour indicators such as alpha-fetoprotein. Patients received 12 mg of lenvatinib orally once a day for body weight ≥ 60 kg or 8 mg for body weight < 60 kg. Sintilimab (200 mg) was administered intravenously each time. Patients were administered TKIs and PD-1 antibodies within 3 d after the start of TACE.
Sun S.S., Guo X.D., Li W.D, & Chen J.L. (2024). Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma. World Journal of Clinical Cases, 12(2), 285-292.
Publication 2024
4
Sintilimab Enhances AP Regimen for Cancer
The patients were divided into an observation group treated with sintilimab injection and the AP regimen (n = 16) and a control group treated with the AP regimen only (n = 16). Both groups received the AP regimen, which consisted of intravenous injection of 25 mg/m² doxorubicin on days 1–3 and 100 mg/m² of cisplatin by intravenous drip for 24 hours on day two, with each cycle lasting 21 days. Both groups of patients were treated for six cycles. The observation group was also administered 200 mg of sintilimab by intravenous drip every three weeks on the first day of chemotherapy.
Li F., Zhang D.B., Ma Y., Song Y, & Duan X.L. (2024). Effects of combined sintilimab and chemotherapy on progression-free survival and overall survival in osteosarcoma patients with metastasis. Pakistan Journal of Medical Sciences, 40(4), 648-651.
Full text: Click here
Publication 2024
5
Diagnosis Criteria for Immune-Related Pneumonitis
IRP was defined as focal or diffuse inflammation affecting the lungs' soft tissues after initiation of sintilimab treatment.
15 The diagnostic criteria for IRP
16 (link),
17 (link) were (a) lung imaging abnormalities (such as ground glass shadow, patch consolidation, and fiber strip shadow) shown by chest computed tomography (CT) after treatment with sintilimab; (b) exclusion of heart failure and pulmonary embolism by comparing enhanced CT, laboratory indicators, echocardiography, and electrocardiogram; (c) exclusion of pulmonary infections by laboratory indicators and efficacy of antibiotic use; and (d) exclusion of tumor progression by laboratory indicators and pathological results (per the Response Evaluation Criteria in Solid Tumors). In addition, the toxicity of the IRP cases was graded according to the National Cancer Institute CTCAE, version 4.0. Patients who did not have IRP or were alive during data analysis were reviewed at the last follow‐up.
Hong B., Chen R., Zheng C., Liu M, & Yang J. (2024). Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment. Cancer Medicine, 13(3), e6708.
Full text: Click here
Publication 2024

Top products related to «Sintilimab»

1
Pembrolizumab by Merck Group
Sourced in United States, China
Pembrolizumab is a monoclonal antibody used in laboratory research. It targets the PD-1 receptor, a protein that regulates the immune system's response to cancer cells. Pembrolizumab is used to study the role of the PD-1 pathway in various biological processes.
2
Camrelizumab by Jiangsu Hengrui Medicine
Sourced in China
Camrelizumab is a laboratory equipment product developed by Jiangsu Hengrui Medicine. It is a monoclonal antibody designed to target the programmed cell death-1 (PD-1) receptor.
3
Nivolumab by Bristol-Myers Squibb
Sourced in United States, China
Nivolumab is a monoclonal antibody that targets the programmed cell death-1 (PD-1) receptor. It is designed to block the interaction between PD-1 and its ligands, thereby enhancing the immune system's ability to detect and respond to cancer cells.
4
Lenvatinib by Eisai
Sourced in Japan
Lenvatinib is a small-molecule tyrosine kinase inhibitor. It targets multiple receptor tyrosine kinases involved in angiogenesis and tumor proliferation.
5
22c3 pharmdx assay by Agilent Technologies
Sourced in United States, Denmark
The 22C3 pharmDx assay is a laboratory test kit developed by Agilent Technologies. The assay is designed to detect the presence of the PD-L1 protein in tissue samples. The core function of the 22C3 pharmDx assay is to provide quantitative measurement of PD-L1 protein expression levels, which can be used to inform treatment decisions for certain types of cancer.
6
Prism 9 by GraphPad
Sourced in United States, Austria, Germany, Poland, United Kingdom, Canada, Japan, Belgium, China, Lao People's Democratic Republic, France
Prism 9 is a powerful data analysis and graphing software developed by GraphPad. It provides a suite of tools for organizing, analyzing, and visualizing scientific data. Prism 9 offers a range of analysis methods, including curve fitting, statistical tests, and data transformation, to help researchers and scientists interpret their data effectively.
7
Sorafenib by Bayer
Sourced in Germany, United States, Japan, China, Italy, United Kingdom
Sorafenib is a lab equipment product manufactured by Bayer. It is a small-molecule tyrosine kinase inhibitor. Its core function is to inhibit multiple kinases involved in cellular signaling pathways.
8
Regorafenib by Bayer
Sourced in Germany, United States
Regorafenib is a small-molecule multi-kinase inhibitor developed by Bayer for use in laboratory research. It functions by blocking the activity of several enzymes involved in processes such as angiogenesis, oncogenesis, and tumor microenvironment interactions. Regorafenib is commonly used in studies investigating cellular signaling pathways and their modulation.
9
Qiaamp circulating nucleic acid kit by Qiagen
Sourced in Germany, United States, Netherlands, United Kingdom, Italy, Spain, Japan, China, France
The QIAamp Circulating Nucleic Acid Kit is a laboratory equipment product designed for the purification of cell-free circulating nucleic acids (e.g., DNA, RNA) from various biofluid samples such as plasma, serum, or urine. The kit utilizes a spin column-based technology to efficiently extract and concentrate the target nucleic acids for further analysis.

More about "Sintilimab"

Sintilimab is a monoclonal antibody that targets the programmed cell death-1 (PD-1) receptor, a crucial immune checkpoint protein involved in regulating T-cell activation and function.
It is used in the treatment of certain types of cancer by enhancing the body's immune response against tumor cells.
Sintilimab has been shown to be effective in clinical trials for various solid tumors and hematological malignancies.
Researchers can leverage PubCompare.ai to optimize their Sintilimab studies and enhance reproducibility by exploring the latest literature, pre-prints, and patents on this important cancer immunotherapy.
Sintilimab, also known as IBI308, is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor, blocking its interaction with the programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) proteins.
This mechanism of action enhances the body's immune response against cancer cells by preventing the PD-1 pathway from suppressing T-cell activation.
Sintilimab is similar to other PD-1 inhibitors, such as Pembrolizumab, Camrelizumab, and Nivolumab, which have also demonstrated efficacy in the treatment of various cancers.
Additionally, Sintilimab has been studied in combination with other targeted therapies, like Lenvatinib, to explore synergistic effects in improving patient outcomes.
To support Sintilimab research, the 22C3 pharmDx assay can be used to measure PD-L1 expression levels, which may be a biomarker for predicting response to Sintilimab and other PD-1/PD-L1 inhibitors.
Researchers can also leverage Prism 9, a comprehensive data analysis platform, to optimize their Sintilimab studies and enhance reproducibility.
For patients with advanced or metastatic solid tumors or hematological malignancies, Sintilimab may be a treatment option, either as a monotherapy or in combination with other therapies, such as Sorafenib or Regorafenib.
The QIAamp Circulating Nucleic Acid Kit can be used to extract and purify circulating tumor DNA (ctDNA) from patient samples, which may provide insights into the genomic profile of the cancer and help guide treatment decisions.